01—Abstract
Summary
Summary of the 8-K filed July 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported financial results for the quarter ended June 30, 2025 (fiscal quarter ended July 4, 2025) and provided a corporate update in a press release furnished as Exhibit 99.1.
Total revenues were $568.3 milliona, compared with $637.2 million a year earlier, and net product revenues rose to $520.0 million from $437.6 million, primarily on higher sales volume. Collaboration revenues fell to $48.2 million from $199.6 million, reflecting a $150.0 million commercial milestone recognized in the second quarter of 2024. GAAP net income was $184.8 million, or $0.65 per diluted share, versus $226.1 million, or $0.77 per diluted share, in the prior-year quarter; non-GAAP diluted EPS was $0.75 compared with $0.84.
The company maintained its full-year 2025 guidance, with total revenues of $2.25 billion to $2.35 billionb and net product revenues of $2.05 billion to $2.15 billion. The release highlights pipeline and regulatory developments. Positive top-line results from the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer showed a statistically significant overall survival improvement versus regorafenib in the intent-to-treat population, and Exelixis plans to discuss the results with regulators.
Enrollment in the STELLAR-304 pivotal trial in non-clear cell renal cell carcinoma was completed in May 2025, with top-line results expected in the first half of 2026. Exelixis decided not to proceed to phase 3 in the STELLAR-305 head and neck program and discontinued the XL495 program. The company also announced the initiation of the STELLAR-311 pivotal trial in advanced neuroendocrine tumors, and a settlement with Biocon Pharma allowing a generic CABOMETYX launch in the U.S. beginning January 1, 2031, subject to FDA approval and conditions.
Capital allocation and tax items were also disclosed. Under its stock repurchase programs, Exelixis had repurchased $796.3 millionc of common stock at an average price of $36.69 per share as of June 30, 2025, and weighted-average diluted shares decreased to 284.4 million in the quarter. The company estimated a federal cash tax benefit of $147 million from accelerated deduction of previously unamortized domestic R&E expenditures under the One Big Beautiful Bill Act, with no corresponding impact to the federal income tax provision.
02—Key points
Key Highlights
- Total revenues of $568.3 million versus $637.2 million a year earlier; net product revenues of $520.0 million versus $437.6 million, driven by higher sales volume.
- Collaboration revenues of $48.2 million versus $199.6 million, mainly due to a $150.0 million Ipsen commercial milestone recognized in Q2 2024.
- GAAP diluted EPS of $0.65 versus $0.77; non-GAAP diluted EPS of $0.75 versus $0.84.
- Full-year 2025 guidance maintained: total revenues of $2.25–$2.35 billion and net product revenues of $2.05–$2.15 billion.
- STELLAR-303 phase 3 trial of zanzalintinib plus atezolizumab in colorectal cancer met overall survival endpoint versus regorafenib in the ITT population; regulatory discussions planned, with the other dual primary endpoint still proceeding.
- Biocon settlement permits a generic CABOMETYX launch in the U.S. from January 1, 2031, subject to FDA approval; $147 million federal cash tax benefit estimated under the One Big Beautiful Bill Act.
- $796.3 million repurchased under stock buyback programs at an average $36.69 per share as of June 30, 2025.
03—Questions
Frequently Asked Questions
How did Exelixis perform in the second quarter of 2025?
Total revenues were $568.3 million, down from $637.2 million, because the prior-year quarter included a $150.0 million Ipsen milestone. Net product revenues grew to $520.0 million from $437.6 million, and GAAP net income was $184.8 million, or $0.65 per diluted share.
Did Exelixis change its 2025 financial guidance?
No. The company stated it is maintaining its previously provided 2025 guidance, including total revenues of $2.25 billion to $2.35 billion and net product revenues of $2.05 billion to $2.15 billion. It noted it will track the early CABOMETYX NET launch and provide updates as appropriate.
What are the key zanzalintinib development updates?
STELLAR-303 in colorectal cancer produced positive top-line overall survival results versus regorafenib, and the company plans to discuss them with regulators. STELLAR-304 completed enrollment with top-line results expected in the first half of 2026. Exelixis will not proceed to phase 3 in STELLAR-305 head and neck cancer, and it initiated the STELLAR-311 pivotal trial in advanced NET.
What did the Biocon settlement agree to?
Exelixis settled its patent litigation with Biocon Pharma Limited and will grant Biocon a license to market a generic version of CABOMETYX in the U.S. beginning January 1, 2031, if approved by the FDA and subject to customary conditions and exceptions.
What share repurchase activity has Exelixis completed?
Under programs authorized in August 2024 and February 2025, each for up to $500 million with a December 31, 2025 deadline, Exelixis had repurchased $796.3 million of common stock at an average price of $36.69 per share as of June 30, 2025. Weighted-average diluted shares fell to 284.4 million, from 326.3 million at the start of the first program in March 2023.
04—Continue